Hospital
State of Mississippi - University of Mississippi Medical Center
State of Mississippi - University of Mississippi Medical Center was paid $7.52M by Medicaid between Jan 2018 and Dec 2024, across 109 billing codes. Its largest line is 99283, emergency room visit (moderate) — 16% of everything it billed.
33Billing provider infoSTATE OF MISSISSIPPI - UNIVERSITY OF MISSISSIPPI MEDICAL CENTER
LEXINGTON, MS 39095
LEXINGTON, MS 39095
33aNPI1386630705assigned 09/21/2005
33bProvider typeCritical Access Hospital
28Total paid$7.52M
24GClaims230,509
24DCodes billed109
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Critical Access Hospital providers in Mississippi
Rank by total paid#7 of 32
Median peer was paid$3.94M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 36,596 | $1.20M | |
| 2019 | 34,698 | $1.30M | |
| 2020 | 26,173 | $875K | |
| 2021 | 31,138 | $997K | |
| 2022 | 39,295 | $1.06M | |
| 2023 | 38,258 | $1.18M | |
| 2024incomplete | 24,351 | $895K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 16% | 10,661 | 8,570 | $1.19M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 14% | 7,815 | 5,897 | $1.02M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 4,310 | 3,388 | $764K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 9.7% | 9,502 | 7,825 | $727K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.2% | 3,294 | 2,646 | $313K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 3.9% | 7,335 | 1,834 | $293K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.8% | 1,765 | 1,124 | $282K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.9% | 4,076 | 2,393 | $218K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.6% | 4,670 | 3,952 | $199K |
| 71046 | Radiologic examination, chest; 2 views | 2.5% | 4,736 | 3,386 | $184K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.2% | 1,769 | 1,446 | $165K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 2.1% | 1,462 | 1,068 | $154K |
97 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 7,341 | $152K |
| 71045 | Radiologic examination, chest; single view | 2.0% | 6,199 | $150K |
| G0378 | Hospital observation service, per hour | 1.9% | 745 | $146K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 8,080 | $111K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 16,927 | $97K |
| 83880 | 1.1% | 3,936 | $80K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.0% | 1,456 | $77K |
| 80053 | Comprehensive metabolic panel | <1% | 10,966 | $72K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,549 | $67K |
| 87428 | <1% | 1,320 | $61K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 2,290 | $57K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,131 | $57K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,454 | $54K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 498 | $52K |
| 36415 | Collection of venous blood by venipuncture | <1% | 17,071 | $46K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,132 | $45K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 407 | $40K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,494 | $39K |
| 84484 | <1% | 5,976 | $39K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 589 | $35K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,186 | $30K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 796 | $30K |
| 81001 | <1% | 12,703 | $29K | |
| 87070 | <1% | 4,220 | $29K | |
| 80061 | Lipid panel | <1% | 2,824 | $28K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,612 | $26K |
| 81025 | <1% | 3,865 | $25K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,001 | $22K |
| 97161 | <1% | 496 | $21K | |
| 87040 | <1% | 3,003 | $20K | |
| 82803 | <1% | 1,325 | $20K | |
| 72100 | <1% | 334 | $19K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,567 | $18K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 818 | $15K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 140 | $14K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,160 | $11K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 264 | $11K |
| 83690 | <1% | 2,659 | $11K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 192 | $10K |
| 82947 | <1% | 3,649 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,745 | $9K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 444 | $9K |
| 36600 | <1% | 298 | $8K | |
| 87077 | <1% | 1,485 | $8K | |
| 83735 | <1% | 2,311 | $8K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 28 | $7K |
| 83605 | <1% | 1,420 | $6K | |
| 87186 | <1% | 928 | $6K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 244 | $6K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 225 | $5K |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 1,638 | $5K |
| 73562 | <1% | 102 | $4K | |
| 82248 | <1% | 1,079 | $4K | |
| 82150 | <1% | 813 | $4K | |
| 73030 | <1% | 104 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 42 | $3K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 2,472 | $3K |
| 73610 | <1% | 54 | $3K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 28 | $3K |
| 73560 | <1% | 69 | $2K | |
| 87807 | <1% | 204 | $2K | |
| 51702 | <1% | 54 | $2K | |
| 85379 | <1% | 318 | $2K | |
| 74018 | <1% | 36 | $2K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 14 | $2K |
| 85610 | <1% | 544 | $1K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 67 | $1K |
| 73630 | <1% | 15 | $884.78 | |
| 87205 | <1% | 208 | $826.60 | |
| 86885 | <1% | 14 | $825.38 | |
| 87430 | <1% | 71 | $796.12 | |
| 82810 | <1% | 150 | $726.23 | |
| 82550 | <1% | 94 | $701.73 | |
| 86677 | <1% | 46 | $641.19 | |
| 85027 | <1% | 74 | $639.04 | |
| 86900 | <1% | 14 | $619.50 | |
| 82270 | <1% | 191 | $611.38 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 26 | $551.97 |
| 73130 | <1% | 19 | $454.08 | |
| 87420 | <1% | 30 | $373.12 | |
| 84550 | <1% | 85 | $273.16 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 15 | $243.25 |
| 82607 | <1% | 20 | $201.79 | |
| 84439 | <1% | 47 | $188.92 | |
| 86901 | <1% | 14 | $187.27 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,684 | $137.80 |
| 87210 | <1% | 45 | $131.50 | |
| 36000 | <1% | 440 | $119.15 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 452 | $40.69 |
| 85730 | <1% | 14 | $16.83 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 694 | $16.56 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 179 | $12.67 |
| 99217 | 0% | 14 | $0.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 142 | $0.00 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 79 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 82 | $0.00 |
| 90714 | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGRIMSLEY, JEFFREY (CFO)
| Provider | Location | Paid |
|---|---|---|
| State of Mississippi - University of Mississippi Medical Center | Jackson, MS | $506.72M |
| State of Mississippi - University of Mississippi Medical Center | Canton, MS | $13.96M |
| State of Mississippi - University of Mississippi Medical Center | Lexington, MS | $1.07M |
| State of Mississippi - University of Mississippi Medical Center | Jackson, MS | $597K |
| State of Mississippi - University of Mississippi Medical Center | Lexington, MS | $507K |
| State of Mississippi- University of Mississippi Medical Center | Vaiden, MS | $137K |
| State of Mississippi - University of Mississippi Medical Center | Jackson, MS | $82K |
| State of Mississippi-University of Mississippi Medical Center | Grenada, MS | $37K |
| State of Mississippi - University of Mississippi Medical Center | West, MS | $11K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.